



**NCI-FREDERICK
INSTITUTIONAL BIOSAFETY COMMITTEE**

Minutes
July 17, 2007
NCI-Frederick

The NCI-Frederick Institutional Biosafety Committee was convened at 12:03 p.m. in the Building 549 Executive Boardroom with the following members in attendance:

Ms. Theresa Bell, Secretary	Dr. Henry Hearn
Dr. Randall Morin	Dr. David Garfinkel
Ms. Alberta Peugeot	Dr. Stephen Creekmore
Dr. Bruce Crise	Dr. Stephen Hughes
Dr. Melinda Hollingshead	
Dr. Dan McVicar	

Members not in attendance: Mr. Lucien Winegar, Dr. Jeanne Herring, Dr. Mike Baseler, Ms. Dianna Boissey

Others in attendance: Ms. Cara Leitch, Dr. Robert Thomas

Renewals

Schmidt (07-38 – Study of inherited kidney cancer syndromes, the causative genes, and mouse models of renal cancer)

- This study involves gene trapping done with non-viral elements.
- A3: Be more specific regarding safety precautions.
- Need more specific SOP to address the hazards associated with EBV as well as work specific to primary human cell lines and human blood.
- Clarify why specific cell lines listed in B2 are different than what is listed in B6b.
- C13: There is no reference to a centrifuging process. Will centrifugation be performed? A chemical fume hood is also mentioned. Should biosafety cabinet be checked instead?
- D3a: Cell lines must be screened prior to injection into animals.
- Where will the tissues that come out of the mice go, to whom, and for what purpose?

Dr. McVicar made a motion to conditionally approve the registration with modifications as noted above, Dr. Crise seconded and all were in favor.

Amendments

Poon (P190701JLA01 – Addition of dendritic cells)

- Provide assurance of the source of the donors and/or the dendritic cells that will be used.
- The supernatants could potentially be contaminated, so they should be as careful as possible to minimize that potential.
- Has the material been screened?
- What specific safety measures are in place? SOP #16113 (written by BDP) should apply.
- Clarify if any sharps will be used?

Dr. Hughes made a motion to defer approval, Dr. Crise seconded and all were in favor. Dr. Creekmore abstained from the vote.

Outstanding Items

Ms. Bell briefed the IBC on the outstanding items.

Other Business

- BBP: An EHS policy will be drafted to address non-compliant personnel with respect to Bloodborne Pathogen annual training requirements.
- May and June 2007 minutes will be sent out via email on July 20, 2007 for comment and approval.
- Human subjects research – Questions from Dr. Richman should be added to section D as previously discussed.
- PEP for *Borrelia Burgdorferi*
 - Ms. Peugeot presented a draft protocol developed by Dr. Sauri.
 - How should individuals who are pulling the samples protect themselves?
 - How will the baseline be defined and is pre-screening necessary?
 - A subcommittee will be put together to review the protocol and discuss any remaining issues surrounding this PEP. Proposed subcommittee members include Mr. Winegar, Ms. Bell, Drs. Crise, Creekmore, Garfinkel, Hollingshead, and Thomas, and Ms. Peugeot.
 - An Informed Consent document may be needed for baseline testing.
- Storage of research material
 - There was a discussion regarding the need for PIs who are only storing material to register that material with the IBC. Paperwork should be put in place to document all of the pertinent information, even if their activities are limited to storage only.
 - Drafting a storage only form was discussed and a procedure for storage only will be determined at the August meeting.
- Footwear in Laboratories
 - Responsibility for enforcement of Personal Protective Equipment worn in the laboratory belongs to each individual lab supervisor. EHS may provide assistance

and risk assessments as requested to identify appropriate PPE based on work conditions.

- Reference may be made to the Exposure Control Plan to identify requirements for PPE in laboratories, in addition to OSHA guidance and the BMBL, 5th edition; however, footwear is not specifically addressed as a mandatory requirement.
- OHS has been requested to discuss monthly accidents of interest with the IBC.

The meeting ended at 1:37 p.m.

Theresa D. Bell, MPH, CBSP
IBC Secretary
Biological Safety Officer, EHS

Ms. Cara Leitch
IBC Coordinator
Sr. Safety Specialist, EHS

APPROVED:

Randall S. Morin, Dr. P.H.
Chairman, NCI-Frederick IBC
Director, EHS

Date

xc: All Committee Members
Dr. Reynolds
Mr. Wheatley
Dr. Arthur
Mr. Bufter
Dr. Keimig